Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-Dotatate PRRT in Metastatic GEP-NEN
NCT03422029Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Peking University. Status: unknown.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03422029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422029.